From GlobeNewswire: 2025-05-30 10:10:00

The global Human Papillomavirus (HPV) vaccine market is expected to grow from USD 8.14 billion in 2024 to USD 27.36 billion by 2032, with a CAGR of 16.38%. The U.S. market is projected to reach USD 10.96 billion by 2032, driven by advanced healthcare infrastructure and government support. Global momentum is increasing due to public health emphasis on HPV prevention and the availability of polyvalent vaccines offering protection against multiple HPV strains.

Polyvalent HPV vaccines accounted for over 85% of total revenue in 2024, with Merck’s Gardasil 9 leading the market. Vaccination against HPV-related cancers held about 70% of the market share, while the genital warts segment is growing rapidly. Hospitals and retail pharmacies constituted around 60% of distribution channels in 2024, with online pharmacies emerging as the fastest-growing.

North America dominated the HPV vaccine market in 2024, with strong infrastructure and school-based vaccination programs. The Asia-Pacific region is experiencing rapid growth, driven by increased awareness and government initiatives. Major players include Merck & Co., GlaxoSmithKline, and Serum Institute of India. Recent developments include a lawsuit against Merck over Gardasil and the Indian government’s partnership with Serum Institute for a national immunization drive.



Read more at GlobeNewswire: Global Human Papillomavirus (HPV) Vaccine Market to Hit USD